Table 1.

Novel prospective MCs-targeting drugs.

Target	Name	Mechanism of Action	Characteristics	Reference
IgE-FcεRI	Omalizumab	Prevents free IgE from binding to FcεRI	Dose not effective for all patients	[140]
	Talizumab	Prevents free IgE from binding to FcεRI	Still in clinical trials	[141]
	Ligelizumab	Prevents free IgE from binding to FcεRI, may reduce B cell production of IgE	Combines with IgE more efficiently than Omalizumab	[142]
	Quilizumab	Depletes IgE-producing B cells	Does not seem to reduce allergic reactions	[143]
	MEDI4212	Prevents free/bound IgE from binding to FcεRI; depletes IgE-producing B cells	Probably better than omalizumab when IgE level is high	[144]
Kinases	Fostamatinib	Inhibits Syk	The effect is fast, but the safety is poor	[145]
	GSK2646264	Inhibits Syk	Has potential toxicity	[146]
	WZ3146	Inhibits Lyn/Fyn	Has no clinical data	[147]
	AZD7762	Inhibits Lyn/Fyn	Has cardiotoxicity	[148]
Siglec-8	Lirentelimab	Inhibits FcεRI signaling	The most promising target	[151]
Tregs	-	Induced by low doses of IL-2	Has great potential against food allergy	[130]